Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer

19 juni 2014 uppdaterad av: Copenhagen University Hospital at Herlev
Gene transfer by electroporation (gene electrotransfer) uses short electric pulses to transiently permeabilise the cell membrane enabling passage of plasmid DNA into the cell cytosol. It is an efficient non-viral method for gene delivery to various tissues. In this phase I dose-escalating study, patients will be treated with intramuscular gene electrotransfer of plasmid AMEP. Plasmid AMEP encodes protein AMEP which bind to α5β1 og αvβ3 integrins. Primary end point of the trial is safety and secondary end points are efficacy, pharmacokinetics and evaluation of potential discomfort associated with the treatment procedure using VAS (Visual Analogue Scale).

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Cohorts of 3 patients will be treated with increasing doses of plasmid AMEP. Up to 12 patients will be treated.

Treatment procedure: Local anesthetic is applied to m. quadriceps femoris (thigh muscle) and the skin. An incision of the skin is performed followed by dissection until the muscle is exposed. The surgical procedure is performed by plastic surgeons.

Plasmid AMEP is injected intramuscularly and immediately followed by application of electric pulses via a needle electrode inserted into the muscle. A combination of one high voltage pulse (700V/cm, 100 µs) followed by one low voltage pulse (80 V/cm, 400 ms) will be applied. The wound is sutured and a dressing is applied. Treatment procedure is estimated to 30 minutes.

All patients are hospitalized for 24 hours after treatment for the purpose of evaluation of vital signs, physical examination, AE and SAE recording and pharmacokinetics sampling (blood and urine).

Blood biochemistry including LDH and CK is taken 24 hours post treatment. ECG will be taken before and after treatment. Patients score discomfort or pain from treated area using VAS.

Studietyp

Interventionell

Inskrivning (Faktisk)

7

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Danmark
      • Herlev, Danmark, 2730
        • Depart. of Oncology, Copenhagen Universtiy Hospital Herlev

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age > 18 years.
  • Performance status < 1 (ECOG).
  • Histologically confirmed malignant tumor (solid tumor) of any histology,
  • Metastatic disease. Patients with asymptomatic brain metastases are eligible.
  • Patient should have been offered standard treatment. Patient is eligible if no standard treatment is available or if the patient does not wish to receive standard treatment.
  • Life expectancy ≥ 3 months.
  • Measurable disease defined as at least one measurable lesion according to RECIST 1.1
  • Patient should have adequate organ function:
  • Adequate bone marrow function: Neutrophil count ≥ 1.0 x 109/l (≤ grade 2 CTCAE 4.0); Platelet count ≥ 75 x 109/l (< grade 2 CTCAE 4.0); Hemoglobin ≥ 6,0 mmol/l.
  • Liver: ALAT or ASAT < 3 ULN (< grade 2 CTCAE 4.0); Bilirubin ≤ 1,5 ULN (< grade 2 CTCAE 4.0); APTT within normal range; INR ≤ 1,2 (< grade 1 CTCAE 4.0)
  • Kidney: Plasma creatinin ≤ 1.5 ULN (< grade 2 CTCAE 4.0)
  • At least 4 weeks since any anti-cancer treatment.
  • Men and women of reproductive age must use effective contraception during the study and at least 6 months after administration of plasmid AMEP.
  • Patient should be able to understand the participant information and able to comply with protocol requirements and scheduled visits.
  • Signed informed consent.

Exclusion Criteria:

  • Allergy to the anaesthetic used.
  • Clinical signs of active infection.
  • Implanted pacemaker, defibrillator or any other implanted electronic device.
  • Participation in other clinical trials involving experimental drugs or participation in a clinical trial within 4 weeks before initiation of study treatment.
  • AMI (acute myocardial infarction), stroke or acute ischemic event within the last 6 months.
  • Severe atherosclerosis, significant cardiovascular disease (NYHA III or IV) or significant arrhythmias.
  • Systolic blood pressure above 180 mm Hg and/or diastolic blood pressure above 110 mm Hg. If BP >180/110 mm Hg medical correction is allowed and the patient can be included when BP < 180/110 mm Hg.
  • Pregnancy and lactation.
  • Clinically significant coagulopathy.
  • Treatment with anticoagulant drugs.
  • Other disorders which the investigator finds incompatible with participation in the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety of the trial treatment
Tidsram: From treatment to last follow up, planned 8 weeks.
Safety is evaluated by registration of adverse events (Adverse Events and Serious Adverse Events) using the CTCAE criteria version 4.0. Patients are seen in the out patient clinic once a week during the first month after treatment (at day 8, day 15, day 22, day 29) and 8 weeks after treatment. If no progression of the disease at 8 weeks, patients are seen at 12 weeks and then every three months until disease progression or death.
From treatment to last follow up, planned 8 weeks.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Efficacy of the trial treatment
Tidsram: PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.
PET/CT scan will be evaluated using RECIST 1.1 (CT) and PERCIST (PET)
PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.
Pharmacokinetics
Tidsram: Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.
Measurements of plasma and urine plasmid AMEP concentrations. Measurements of plasma and urine protein AMEP concentrations
Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.
Discomfort associated with the treatment procedure
Tidsram: Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.
The patient completes VAS (Visual Analogue Scale) scores pain related to the treatment area at abovementioned time points.
Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.
Safety
Tidsram: Day after treatment and 14 days after treatment
MR scan of treated region (thigh muscle) in order to assess potential intramuscular edema or hematoma
Day after treatment and 14 days after treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Copenhagen University Hospital at Herlev

Utredare

  • Huvudutredare: Julie Gehl, MD DMSci, Department of Oncology, Copenhagen University Hospital Herlev

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 juli 2012

Primärt slutförande (Förväntat)

1 maj 2015

Avslutad studie (Förväntat)

1 maj 2015

Studieregistreringsdatum

Först inskickad

16 juli 2012

Först inskickad som uppfyllde QC-kriterierna

10 augusti 2012

Första postat (Uppskatta)

14 augusti 2012

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

20 juni 2014

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

19 juni 2014

Senast verifierad

1 juni 2014

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • AA 1201

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Metastatisk malign neoplasm

Kliniska prövningar på Plasmid AMEP

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Indonesia

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera